Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM) patients (n = 27). Response was analyzed 1 month after the second dose of anti-SARS-CoV-2 BNT162b2 vaccine. Multiple myeloma patients showed diminished levels of Anti-Spike IgG levels compared to controls, but with a high proportion of patients achieving a humoral response (89% vs. 97% in controls). Neutralizing antibodies were present in 74% of patients versus 96% of controls. Patients under current daratumumab treatment had neutralizing activity of anti-SARS-CoV-2 antibodies. Multiple myeloma patients show diminished response to SARS-COV-2 vaccine but with still high response rate. The main potential risk factor of non-response to COVID-19 vaccine was uncontrolled disease under treatment.

中文翻译：

---

多发性骨髓瘤对 COVID-19 mRNA 疫苗接种的反应是保守的，但与对照组相比有所减弱

多发性骨髓瘤患者患严重形式的 COVID-19 的风险很高。尽管数据显示对疫苗的反应减弱，但高效 mRNA 疫苗的时代可能会改变游戏规则。我们试图检查健康对照 (n = 28) 和多发性骨髓瘤 (MM) 患者 (n = 27) 之间对 mRNA 疫苗的反应。在第二剂抗 SARS-CoV-2 BNT162b2 疫苗接种后 1 个月对反应进行了分析。与对照组相比，多发性骨髓瘤患者的抗刺突 IgG 水平降低，但有很高比例的患者达到体液反应（对照组为 89% 与 97%）。74% 的患者与 96% 的对照组存在中和抗体。目前接受达雷妥尤单抗治疗的患者具有抗 SARS-CoV-2 抗体的中和活性。多发性骨髓瘤患者对 SARS-COV-2 疫苗的反应减弱，但反应率仍然很高。对 COVID-19 疫苗无反应的主要潜在风险因素是治疗中的疾病不受控制。